|
PGEN | Precigen, Inc. |
|
|
PGEN | Precigen, Inc. |
| Pharmaceutical Preparations |
| Book value per $ invested | $ 0.14 |
| Leverage | 54.06% |
| Market Cap | $ 487.9m |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -125.8m |
| Margin | -5952.77% |
Precigen, Inc. discovers and develops the next generation of cell and gene therapies in the United States. The company is headquartered in Germantown, Maryland.